31 July - Wednesday

Preliminary program - subject to change.

09:00 - 10:00

Plenary Lecture 3

10:00 - 10:30

Refreshment Break with Exhibitors and Posters

10:30 - 12:30

Concurrent Sessions: Symposia 9 and 10

Symposium 9: Role of Albumin in Drug Disposition Revisited
Co-Chairs: Malcolm Rowland, University of Manchester, Manchester, United Kingdom and Stephen Hall, Eli Lilly and Company, Indianapolis, IN, USA

Albumin-mediated Hepatic Uptake of Organic Anion Transport Polypeptide Substrates
Yuichi Sugiyama, Sugiyama Laboratory, RIKEN Baton Zone Program, RIKEN, Yokohama, Kanagawa, Japan

Effects of Albumin on Prediction of Liver Kpuu and Human Hepatic Clearance for Enzyme- and Transporter-Mediated Mechanisms
Li Di, Pfizer Inc., Groton, Connecticut, USA

Speaker to be Confirmed

Symposium 10: Ontogeny of Enzymes and Transporters and their Implications in Pediatric PBPK Modeling to Inform Pediatric Dosing

Co-Chairs: J. Steven Leeder, Children's Mercy Hospital, Kansas City, Missouri, USA and Ping Zhao, Bill & Melinda Gates Foundation, Seattle, Washington, USA

Ontogeny of Human Membrane Transporters: from Data to Application
Saskia de Wildt, Radboud University Medical Center, Nijmegen, Netherlands

Pediatric PBPK: Dealing with Uncertain Parameters and Deciding on Success Criteria for Predictability
Trevor Johnson, Certara UK Limited (Simcyp Division), Sheffield, United Kingdom

Use of ‘Virtual Children’ to Inform Exposure-Controlled Dosing of Drugs in Children
Jean Dinh, Children's Mercy Hospital, Kansas City, Missouri, USA

Building, Verifying and Validating Pediatric PBPK Models: Vulnerabilities and Knowledge Deficits
Ping Zhao, Bill & Melinda Gates Foundation, Seattle, Washington, USA

Lunch with Exhibitors and Poster Presentations

12:30 - 14:30

ISSX Awards Presentations and Lectures

14:30 - 16:00

16:00 - 18:00

Plenary Symposium 11

Symposium 11: ‘War Stories’ – ADME Issues Encountered and Addressed in Drug Discovery and Development
Co-Chairs: Marcel Hop, Genentech Inc, South San Francisco, California, USA and Deepak Dalvie, Celgene, San Diego, California, USA

Navigating through Clinical Development Painlessly: Snapshots within the Nav1.7 Program
Jae Chang, Genentech Inc, South San Francisco, California, USA

Elagolix: A Mechanistic Understanding of Drug-Drug Interactions
Marjoleen Nijsen, Abbvie, Chicago, Illinois, USA

ZEPATIER: The Tale of Two Novels
Christine Fandozzi, Merck & Co. Inc., USA

Management of MIST in a Case of Multiple Metabolic Species Differences
Lars Weidolf, AstraZeneca, Mölndal, Sweden

18:00 - 18:30

Closing Session

18:30 - 19:00

Networking Happy Hour at Spirit of 77

Join fellow attendees for arcade games, upscale bar fare, craft beers and cocktails before you head home from the meeting.